Orphazyme publishes listing prospectus in connection with listing of shares
Mar 16, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces the publication of a listing prospectus (the “Listing Prospectus”) prepared for the purposes of admitting 3,071,673 shares of nominal value DKK 1 each (the “Listing Shares”) to trading and official listing on Nasdaq Copenhagen A/S under the permanent ISIN code DK0060910917 (the “Listing”).
Orphazyme publishes listing prospectus ...
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Mar 11, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in Orphazymes shares made
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Mar 10, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in orphazyme s shares made
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Mar 4, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in orphazymes shares made
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Mar 3, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in orphazymes shares made
Read moreNotice to convene AGM
Mar 3, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the Orphazyme A/S Annual General Meeting will be held on.
Appendix 2 revised remuneration policy
Appendix 1 candidates for the board of directors
Read moreMajor shareholder announcement
Mar 2, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of February 27, 2020 holds a total 1,244,908 shares in the Company, corresponding to 4.60% of the share capital and that Danske Bank as of February 27, 2020 controls 6.72% of the voting rights in the Company.
Major shareholder announcement
Read moreOrphazyme announces Annual Report 2019
Feb 28, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces its Annual Report for the period January 1–December 31, 2019.
Orphazyme announces annual report 2019
Read moreOrphazyme to present at Cowen & Company 40th Annual Health Care Conference
Feb 27, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that Kim Stratton, Chief Executive Officer at Orphazyme, will present at the Cowen & Company 40th Annual Health Care Conference taking place March 2-4, 2020, in Boston, United States.
Orphazyme to present at cowen company 40th annual ...
Read moreOrphazyme Annual Report 2019 Presentation
Feb 20, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that the Company will be hosting an investor call at which Chief Executive Officer, Kim Stratton, and Chief Financial Officer, Anders Vadsholt, will be presenting the Orphazyme Annual Report 2019. The presentation will be followed by a Q&A session.
Orphazyme annual report 2019 presentation
Read more